Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: GlobalData
$250.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Zynex Inc Lowers FY 2013 Guidance


Friday, 12 Jul 2013 03:24pm EDT 

Zynex Inc announced that During the first half of 2013 the Company encountered industry challenges related to health care reform that has affected its Zynex Medical electrotherapy business. Specifically, because of reimbursement changes for durable medical equipment, uncertainty continues to exist at the medical practitioner level causing a delay and decline in demand for the Company's Zynex Medical electrotherapy products. The Company has also experienced reimbursement challenges from government and third party payors related to certain medical indications for its Zynex Medical electrotherapy products, which is negatively impacting the Company's revenue. These market factors will have a negative effect on the Company's financial results for the second quarter and full year 2013, resulting in the Company not meeting its original revenue and earnings guidance. Revenue for the second quarter and full year 2013 will be significantly less than anticipated and the Company expects to record a net loss for the second quarter and full year 2013. 

Company Quote

0.2
-0.02 -9.09%
8 Sep 2014